Direkt zum Inhalt
Merck
Alle Fotos(2)

Wichtige Dokumente

Gesamtdokumentation anzeigen

H0627

Sigma-Aldrich

6-Hydroxymelatonin

Synonym(e):

3-(N-Acetylaminoethyl)-6-hydroxy-5-methoxyindole

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

Empirische Formel (Hill-System):
C13H16N2O3
CAS-Nummer:
2208-41-5
Molekulargewicht:
248.28
MDL-Nummer:
MFCD00037971
UNSPSC-Code:
41116107
PubChem Substanz-ID:
24278458
NACRES:
NA.77

Löslichkeit

alcohol: soluble

Qualitätsniveau

100

SMILES String

COc1cc2c(CCNC(C)=O)c[nH]c2cc1O

InChI

1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16)

InChIKey

OMYMRCXOJJZYKE-UHFFFAOYSA-N

Angaben zum Gen

human ... MTNR1A(4543) , MTNR1B(4544)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

6-Hydroxymelatonin (6-OHM) is a melatonin metabolite. It is produced in the liver by the action of cytochrome P450 enzyme as well as by photodegradation of melatonin. In the central nervous system, it exists as a sulfated form. 6-OHM is a partial melatonin receptor MT2 agonist.

Anwendung

6-Hydroxymelatonin has been used as a melatonin derivative to test its protective effects in ultra violet B (UVB)-induced oxidative stress melanocytes and keratinocytes.

Biochem./physiol. Wirkung

6-Hydroxymelatonin (6-OHM) is an antioxidant with a free radical scavenging role. Like melatonin, it reduces the impact of UVB-induced oxidative stress in melanocytes. It also aids protection during iron (Fe2+)-induced neurotoxicity. 6-OHM effectively reduces lipid peroxidation and superoxide anion production induced by potassium cyanide (KCN).

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

H-Sätze

H302,H351

Gefahreneinstufungen

Acute Tox. 4 Oral - Carc. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Persönliche Schutzausrüstung

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
MKCQ5276
MKCP1225
MKCN2451
MKCM5782
MKCJ4551

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Deepa S Maharaj et al.
Journal of neurochemistry, 96(1), 78-81 (2005-11-23)
Oxidative damage of biological macromolecules is a hallmark of most neurodegenerative disorders such as Alzheimer, Parkinson and diffuse Lewy body diseases. Another important phenomenon involved in these disorders is the alteration of iron homeostasis, with an increase in iron levels.
Xuwan Liu et al.
American journal of physiology. Heart and circulatory physiology, 283(1), H254-H263 (2002-06-14)
The present study was designed to explore the protective effects of melatonin and its analogs, 6-hydroxymelatonin and 8-methoxy-2-propionamidotetralin, on the survival of doxorubicin-treated mice and on doxorubicin-induced cardiac dysfunction, ultrastructural alterations, and apoptosis in mouse hearts. Whereas 60% of the
Katsuhisa Sakano et al.
Biochemical pharmacology, 68(9), 1869-1878 (2004-09-29)
Melatonin, an indolic pineal hormone, is produced primarily at night in mammals and is important in controlling biological rhythms. Although melatonin is known to be effective as a free radical scavenger and has an anti-cancer effect, carcinogenic properties have also
G Facciolá et al.
European journal of clinical pharmacology, 56(12), 881-888 (2001-04-25)
The present study was carried out to identify the cytochrome P450 enzyme(s) involved in the 6-hydroxylation and O-demethylation of melatonin. The formation kinetics of 6-hydroxymelatonin and N-acetylserotonin were determined using human liver microsomes and cDNA yeast-expressed human enzymes (CYP1A2, 2C9
S Härtter et al.
Therapeutic drug monitoring, 23(3), 282-286 (2001-05-22)
Melatonin has recently garnered interest as a possible treatment for sleep disorders, and this has created a desire for appropriate pharmacokinetic studies. No method has yet been published that can measure the concentrations of both melatonin and its main metabolite
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.